Kimberly-Clark Acquires Kenvue to Strengthen Consumer Health Portfolio
Article excerpt
Highlighted: the sentence this signal was extracted from
Kimberly-Clark Corporation is acquiring Kenvue Inc., the former consumer health business of Johnson & Johnson, as reported by Detik Finance from CNBC's Mad Money episode on Tuesday. The move establishes a defensive holding for investors reallocating from volatile technology stocks into lower-risk value assets. The strategic acquisition grants Kimberly-Clark control over widely used consumer health staples, including Tylenol, Neutrogena, Listerine, and Band-Aids. According to host Jim Cramer, the transaction provides a steady cash flow stream and a bottom for the stock after extended price struggles. "This one's finally found its footing after struggling for years. Best of all, Kimberly-Clark realized it needs to consolidate, which is why it's acquiring Kenvue, J&J's old consumer health business. I want you to think there… Tylenol, Neutrogena, Listerine, Band-Aids. These are everyday necessities that consumers buy regardless of the state of the economy or the price of gasoline. Doesn't hurt that Kimberly-Clark will pay you handsomely while you wait for the deal to close," said Jim Cramer, Host of CNBC's Mad Money. The combination offers potential long-term revenue growth, improved operating margins, and structural cost reductions. It also serves as a safeguard against foreign competition by leveraging constant demand for health and wellness products regardless of broader fuel...
Keep reading with a free account
The rest of this article, and every signal for Kimberly-Clark, is in your free account.
